Registries and cord blood banks around the world collect and store the HLA types of volunteers in order to identify matched unrelated donors for patients requiring hematopoietic stem cell transplantation. This task is complicated by the many formats in which HLA types are provided by the testing laboratories (types obtained by serology vs by DNA-based methods; high vs intermediate vs low resolution) and by the need to identify which of these diverse types are most likely to match the HLA assignments of a searching patient as closely as possible. Conversion of the assignments to 'search determinants' may be included within the algorithm used to select and prioritize a list of potentially suitable donors, either as an aid to matching or as a tool to optimize the performance of comparisons within large data files. The strategies used by registries to create search determinants are described. A set of search determinants, utilized by the National Marrow Donor Program, is provided as an example and is intended to initiate further discussion aimed at understanding the process used by each registry with the possibility of developing a standard process among registries worldwide. (Table 1) . As the complexity of HLA nomenclature increases 1 and as registries seek to exchange information to facilitate the world-wide search for unrelated donors, 2-4 it becomes critically important to clarify and perhaps even standardize the types of HLA assignments that are accepted into a registry, how assignments are compared, and how potential donors are identified within each registry. This document provides guidelines and suggests strategies for comparing the HLA assignments in order to identify potentially matched donors for a specific patient. Issues involving the limitations in the approaches used to interpret primary typing data obtained from DNA assays and the complications that this creates for registries have already been discussed.
Registries and cord blood banks around the world collect and store the HLA types of volunteers in order to identify matched unrelated donors for patients requiring hematopoietic stem cell transplantation. This task is complicated by the many formats in which HLA types are provided by the testing laboratories (types obtained by serology vs by DNA-based methods; high vs intermediate vs low resolution) and by the need to identify which of these diverse types are most likely to match the HLA assignments of a searching patient as closely as possible. Conversion of the assignments to 'search determinants' may be included within the algorithm used to select and prioritize a list of potentially suitable donors, either as an aid to matching or as a tool to optimize the performance of comparisons within large data files. The strategies used by registries to create search determinants are described. A set of search determinants, utilized by the National Marrow Donor Program, is provided as an example and is intended to initiate further discussion aimed at understanding the process used by each registry with the possibility of developing a standard process among registries worldwide. Keywords: registry; hematopoietic stem cell transplantation; HLA Selection of an unrelated donor for hematopoietic stem cell transplantation is based primarily on HLA matching. The information systems of registries of adult volunteer donors or banks with umbilical cord blood units collect, store, and compare HLA assignments of searching patients to the donors listed. (The word 'registry' as used in the remainder of this document is meant to include both registries of adult volunteers and umbilical cord blood banks.) These assignments are submitted by many different laboratories testing on behalf of transplant centers or donor recruitment centers. The assignments are obtained by serologic and/or DNA-based typing methods, and are provided at various levels of 'resolution' ( Table 1) . As the complexity of HLA nomenclature increases 1 and as registries seek to exchange information to facilitate the world-wide search for unrelated donors, [2] [3] [4] it becomes critically important to clarify and perhaps even standardize the types of HLA assignments that are accepted into a registry, how assignments are compared, and how potential donors are identified within each registry. This document provides guidelines and suggests strategies for comparing the HLA assignments in order to identify potentially matched donors for a specific patient. Issues involving the limitations in the approaches used to interpret primary typing data obtained from DNA assays and the complications that this creates for registries have already been discussed. [5] [6] [7] [8] 
HLA assignments for donors and patients
Usually, HLA-A, -B, and -DR types are assigned for volunteer donors and patients seeking an unrelated donor, and search algorithms are based on matching only for these three loci. Registries may also receive information on other HLA loci such as HLA-C or -DQ. These secondary assignments for donors are stored by registries and may appear on search reports, but are not usually included in the matching algorithms. As more data are collected on the role that these 'secondary' loci play in transplant outcome, registry search and matching algorithms may also need to evaluate matching at these loci. For example, a recent report suggests that HLA-C matching should be given the same priority as HLA-A, -B, and -DR matching. 9 In order to effectively include HLA-C in matching, registries will need to focus on typing volunteers for HLA-C at recruitment.
In general, it is recommended that registries accept only those assignments which use HLA nomenclature that has been approved by the WHO HLA Nomenclature Committee. 1, 10 For example, a DNA-based assignment not listed on the HLA nomenclature web site (eg, B*62) should not be accepted. Registries may have historically accepted donor assignments not listed on the website, and it is recommended that these donors be retyped or assignments reinterpreted to conform to the recommended nomenclature. DNA nomenclature must be used for assignments made using molecular biology testing methods (eg, sequence-specific priming) and serologic nomenclature for results obtained by assays using antibody reagents. Conversion of typing results such as the conversion of results obtained by DNA-based typing to serologic assignments by a source other than the registry itself should be discouraged. This ensures consistency in the assignments.
One exception to the use of WHO HLA assignments is the use of registry-specific nomenclature to capture the many alternative allele combinations obtained by low-tointermediate resolution testing. The National Marrow Donor Program (NMDP) has developed a 2-4 letter code to summarize these possibilities (eg, DRB1*11AD is the equivalent of DRB1*1101 or DRB1*1104). 11 This registryspecific nomenclature arose from the need to represent the HLA types of volunteer donors in the limited space of a printed search report, and these codes are now adopted by many other registries.
If the registry has a limited number of character positions in the fields for HLA assignments, a format to report null (nonexpressed) alleles and silent (synonymous) substitutions should be in place, since these HLA names can be longer than four digits. For example, B*15010102N is a nonexpressed allele, while B*15010101 is a similarly named but expressed allele. Identification of the null allele is important for matching, since no protein product is expressed on the cell surface. This allele may be reported without the accompanying 'N', since B*15010102 is also a correct designation although the 'N' adds additional confirmation of the nature of the allele. However, collapse of the assignment back to a smaller number of digits, such as B*1501, would be incorrect, since this designation also includes the more common expressed allele B*15010101. On the other hand, alleles that only differ by silent substitutions such as DRB1*110101 and DRB1*110102 are not important to distinguish for matching, since their protein products are identical. In these cases, the results might be reported as DRB1*1101 although the loss of information may prove a drawback over time. For example, A*020101 is identical to a nonexpressed allele, A*0243N, in the exons usually characterized by typing (ie, exons 2 and 3). A*020102 differs from A*0243N in these exons. Therefore, a typing of A*020102 clearly indicates that an expressed allele is present; collapse of that assignment to A*0201 loses this information.
The registry must also plan for future changes in allele designations. For example, discovery of a new allele that differs from a previously described allele by a silent substitution or a difference outside the coding region may result in the older allele name being altered by the HLA Nomenclature Committee by the addition of extra digits. This situation is analogous to the splitting of a serologic broad designation. For example, in 1998, B*1501 was subdivided into B*1501101 and B*1501102N. Further changes occurred in 2002 when the names were again changed to B*15010101 and B*15010102N to accommodate changes in the nomenclature brought about by the rapid increase in new alleles. Alleles may also be deleted if found to be in error (eg, actually identical to a previously designated allele) or renamed to reflect similarities to other alleles not realized at the initial assignment (eg, B*1522 was recently renamed B*3543). 1 Communication between registries, represented by the World Marrow Donor Association Information Technology (IT) Working Group, and the WHO HLA Nomenclature Committee will allow nomenclature changes to be considered within the donor selection and economic constraints of the registries, the largest users of HLA data in the world.
Additional typing results
Since donors may be tested more than once, most registries develop a strategy for how HLA typing results will be summarized into an assignment used for comparison with the patient's type. For example, the original typing of a donor may be obtained by serology. Later, that donor might be selected as a potential match for a patient and confirmatory and/or higher resolution typing obtained for the same loci. The registry should have a policy prioritizing the typing results such as DNA typing results overriding serologic assignments or higher-resolution results overriding lower-resolution results. It should be noted that the most recent typing results are not always the 'best' results, since the quality or resolution of the result will depend on the laboratory providing the data. A process for evaluating apparently different typing results should also be in place. This comparison process can be used as a quality control for registry typing.
All typings should be retained in a history file associated with that donor. Although the DNA-based typing is more likely to be used in the donor search, serologic data will confirm the absence of nonexpressed alleles.
It is possible that the typing of a single locus might be obtained by both serology and DNA (eg, donor typed as DR7, DRB1*0405). In these cases, the donor may have been originally typed by serology, selected as a potential donor for a patient, and high-resolution testing applied only to one of the DR alleles to determine if the donor would be an allele match. In this example, high-resolution typing was performed only to resolve the DR4 assignment, because the assumption was made that the same DR7-associated allele DRB1*0701 is common in all populations. Also, in many cases, transplant programs order tests for only one allele at a time because of financial constraints. Since these mixed assignments are difficult to handle within the matching algorithms, they should be discouraged.
Search determinants
The registry determines which HLA assignments might be considered matches or potential matches during the donor search. This is complicated by the variety of HLA assignments in the registry, as described above. The usual approach is to convert each HLA assignment into a common 'language' or search determinant (s.d.). Individuals who share search determinants are judged to be matched or potentially matched for that HLA assignment. Thus, a knowledge of the relationships between DNA assignments and serologic types is essential for the development of s.d.
12,13 The use of s.d. also speeds the selection of potential donors within large data files, sometimes containing the HLA types of up to several million individuals.
The s.d. may be based on the known serologic relationships between alleles and antigens (eg, s.d. for HLA-B*1501 would be based on the serologic specificity, 62) or they may be based on the DNA nomenclature (eg, s.d. for HLA-B*1501 would be based on the first two digits of the allele name, 15). The NMDP currently uses the former for class I s.d. and the latter for DR s.d., a decision based on the predominance of serologic vs DNA-based assignments of HLA-A, -B vs -DR loci, respectively, at the time of implementation (1997).
For registries that identify potential allele matched donors, the s.d. matching process is followed by a second-stage analysis which compares the original typing assignments and prioritizes actual or potential allele matches. For example, in the NMDP system, DRB1*0401 and DRB1*0405 are both assigned a s.d. of 04, indicating their match at the antigen level (both DRB1*04, both serologically DR4). Once identified as a s.d. match, the search algorithm further evaluates matching based on a comparison of the alleles identified. In this example, DRB1*0401 vs DRB1*0405 matches would be prioritized lower than two individuals sharing DRB1*0401. Table 2 shows one example of search determinants with relationships shown at the 'antigen' level of match.
Balancing the need to identify all potentially matched donors
Most registries adopt a strategy in which no potentially matched donors are likely to be missed during the search. 14 For example, the registry might decide that B64 and B65 (splits of B14) are inconsistently defined, and so might assign a search determinant of 14 to both. Therefore, when a B64-positive patient searches for a matched donor, both B64 and B65 typed donors will appear on the search report. In these cases, the registry may sort the resultant donor list so that the most likely potential matches appear at the top of the list. This inclusive approach must be balanced, however, with the need to provide a limited list of potential donors to the transplant center. If the relationships between search determinants are defined too broadly, the potential donor list will be long and will contain donors whose HLA assignments are not likely to actually match the patient's HLA types. This may confuse transplant centers that are less experienced in the complexities of HLA and the centers may miss potentially excellent matches within the large lists.
The length of the potentially matched donor list is also affected by the resolution of the patient HLA types. The higher the resolution, the more limited the list will be and matched or potentially matched donors will be easier to identify. This is particularly helpful at the initial stages of the search when the transplant center is seeking information on the overall availability of matched donors in making a decision to proceed with transplantation using an unrelated donor.
The inclusion of newer HLA alleles into the registry database and algorithms
Registries should design their s.d. to address all known HLA alleles, since any given patient or donor typing may include the most recently described or rare alleles. (It is a requirement of HLA typing standards that typing results obtained by a laboratory include all possible alternative alleles from among the known alleles (eg, www.ashi-HLA.org)). To facilitate rapid entry and search of these typing results, the registry must have a system in place to add new alleles with search determinants as required.
Complexities in assignment of search determinants and relationships for alleles
The assignment of search determinants and recommendations for their use can take into account the relative likelihood of different possibilities, the complex nature of the HLA system, and limitations in the testing methods and nomenclature. Some of those situations are discussed below.
Unknown relationship between serologic and DNA assignments. Some alleles have not been assigned serologic types. For example, no one has used serologic reagents to test any cell carrying DRB1*0430. In these cases, the registry must predict what the serologic type of that allele might be in order to link the allele to a serologically typed donor. The name of the allele might be used to predict the type (DRB1*04 will type as DR4); however, since the name is selected based on nucleotide sequence homology, it is not always predictive of the serology. The search determinant selected might be based on the serologic broad or split specificity; usually the broad is the safest if the serology is not known. For example, the serologic type of B*4015 is not known. In this case, it might be assigned a search determinant of B40 rather than B60 or B61, the serological splits of B40. In some cases, the serology might be predicted based on specific shared sequences or other computational approaches, 13 but this requires an HLA expert for assistance. Such predictions can be practically relevant and should be included and updated on an accessible web site such as that used for HLA nomenclature. 15 Of course, if patients carrying an allele with undefined serology are identified, transplant centers should be encouraged to use serologic typing to collect this information. 12 Limitations in serology. The serologic assignment of some antigens may be inaccurate or unclear. The registry may wish to map search determinants for these serologic types more broadly, in order not to miss any matched donors. One approach is to assign more than one search determinant to a serologic type. For example, DR103 might be assigned a search determinant of 103 and a second search determinant of 01. The latter assignment accounts for any assignments of DR103 as DR1. In another approach taken by the NMDP, broad search determinants might be assigned to all serologic splits of DR (eg, DR16 is assigned a search determinant of 02 in case some DR16 assignments were incorrectly assigned as DR15). If the registry typing has been performed by a single laboratory expert in DR serology, this may not be necessary. Again, if longer lists of donors result, the broad mapping of DR types may be a drawback, as is the case for some of the HLA-A and -B types. Another alternative is to identify mismatches involving the DR splits and report those donors on the search report, sorted below the potential matches.
In the cases where the serologic assignment of an allele is unclear, the registry may link that allele to several different potential serologic specificities. For example, B*8201 has never received a WHO serologic designation. Based on sequence homology and known serological test results, 12 this allele might be typed as B45 or B22. Therefore, the s.d. for this allele might list 45, 22, and 82 to cover all potential serologic assignments as well as all DNA assignments.
Variations in serologic assignment for a specific allele, addressing broad, split, and highly crossreactive antigens. In some cases, a specific allele may be assigned different serologic types in different laboratories. For example, a cell carrying A*6601 might be assigned as A26 or A66. Depending on the quality of the serologic typing in the . In these cases, the search determinant should link these alleles with the serologic types. B*5002 might be assigned a search determinant of 45 þ 50 in order to match it to individuals typed as B45 by serology, and also to DNA-typed individuals assigned B*50.
Blanks, nonexpressed (null), and expression-variant alleles. While many individuals will be heterozygous, carrying two alleles at each HLA locus, some individuals may only receive a single assignment (eg, A*020101 only compared to A*020101, *110101). The absence of an assignment, termed a 'blank', can be caused by homozygosity (eg, A*020101, *020101), the presence of a nonexpressed allele not detected by serologic typing reagents (eg, A2 only with the underlying alleles, A*020101, *0104N); lack of resolution of the typing reagents (eg, A*02 only with underlying heterozygosity of A*020101, *0205), or inability of the reagents to detect a second distinct assignment (eg, a serologic typing of A2 with the undetected presence of A74). 16 These possibilities should be considered in the design of the matching algorithms. For example, a patient typed as A*020101, *0104N should be considered the equivalent of a patient typed as A*0201 only. Furthermore, on a s.d. level, A*0201, A*0104N (SD02) should match with an individual carrying A*0201, *0205 (SD02, 02), for example.
A few alleles carry variations that result in the production of low levels of protein at the cell surface (eg, A*24020102L) or produce a secreted, but not a cell surface, product (B*44020102S). 1 Since initial studies suggest that A*24020102L appears to be immunologically indistinguishable from the normal allele A*24020101; 17 a s.d. of 24 has been assigned to both. At present, there is little information regarding the role of the putative secreted variant B*44020102S, and, since it is not expressed at the cell surface, the NMDP has assigned this allele to the same category as the nonexpressed alleles (no s.d. assigned). Table 3 . It is important for each registry to evaluate the frequencies of HLA types, preferably at the allele level, in the racial/ethnic population groups within its database, so that strategies for assigning s.d. for these complex assignments can be developed.
Alternative alleles with known but different related serologic assignments. If, for example, the alleles potentially carried by a volunteer donor map to different serologic splits of a broad antigen, then the search determinant assigned might reflect the broad specificity. For example, if the assigned allele group includes alternative alleles linked with both the B62 and B75 'splits' of B15, then the search determinant might be 15, reflecting the broad group. In this way, a B62-positive patient will receive reports listing donors with these serologically mixed intermediate assignments. The drawback is that these donors will also appear on searches for patients who are B63, B76, and B77, very different 'splits' of B15. A better alternative is to select two search determinants for that allele combination, 62 and 75.
Alternative alleles with split and broad assignments. These allele results include, for example, a group of B*40 alleles with a known B60 split serologic type and one or more B*40 alleles that are assigned only a broad B40 association, because their serological typing pattern is either unknown or poorly defined. The registry has several choices. It can assign a search determinant linking this typing to all individuals who carry any form of B40 (ie, B40, B60, B61), or it can link it to a single split serologic assignment (ie, in this case, B60), based on a prediction that the undefined B40 assignments might ultimately be assigned to B60. The latter assumption might also be based on the hypothesis that the allele(s) with the broad B40 assignment will be rare and most individuals will carry the more common B60-assigned alleles. This hypothesis should be supported by allele frequency studies from the registry's donor pool. Table 4 illustrates the impact on donor selection for each of these choices.
Alternative alleles with known but different unrelated serologic assignments. These typing results include, for example, B*15, which includes alleles with serologic types in the B15 (B62, B63, B75, B76, B77) and in the B70 (B71, B72) antigen families. The registry has several choices. It can assign a search determinant linking this typing to all individuals who carry B15 and B70 (ie, multiple search determinants, an approach taken by the NMDP and the Canadian UBMDR), or it can link it to a single serologic assignment, based on a prediction as to which serologic type is expected. In the former case, too many donors typed Table 3 Examples of NMDP search determinants used for lowintermediate-resolution HLA types as B*15 appear on the search reports and, in the latter, matched donors may be missed in the search.
Alternative alleles that include some with unknown assignments. These typing results include, for example, B*40, which includes alleles with B40 split serologic types (B60 or B61), alleles with non-B40 types (eg, B*4005 (B50), B*4012 (B48 Â B70)), and alleles with no serologic assignment (eg, B*4013). The registry has several choices: (1) It can assign a search determinant linking this typing to all individuals who carry any form of B40 (ie, B40, B60, B61), B48, B50, and B70; (2) It can link it to all individuals who carry any form of B40 and ignore the additional non-B40 serologic associations; or (3) It can link it to a single split serologic assignment (eg, B60) based on a prediction of allele frequencies. The last approach must consider the differences in allele frequencies within racial/ethnic groups since, for example, alleles encoding the B61 split may be common in Hispanic donors, while the B60 set of alleles are common in non-Hispanic Caucasoid donors. 18 Table 4 illustrates the impact on donor selection for these and other choices.
Another example in this category includes alleles that are clustered as an intermediate resolution assignment by DNA typing because of shared sequence polymorphisms (eg, DRB1*04 plus DRB1*1122). In this case, a s.d. should link this intermediate result to 04 and 11 to include all possible DNA-typing results with these alleles, as well as all expected serologic types. (The serologic specificity of DRB1*1122 is not known.)
Alternative alleles including some with null assignments. These typing results include, for example, A*01, which includes the nonexpressed allele A*0104N. The registry might assign a search determinant linking this typing result to all individuals who carry any form of A*01. Since most nonexpressed alleles are expected to be rare, 16 this approach is acceptable.
Crossreactive antigens
Some registry algorithms list donors who carry HLA-A, -B antigens that are crossreactive with the patient's antigens. This may include different splits within the same broad serologic assignment (eg, A68 donor and A69 patient) or antigens that belong to the same serological crossreactive group (CREG). 19 These donors might be included in the lists of potentially matched donors for two purposes.
First, and more commonly, when a well-matched donor is not available, these mismatched donors might be considered by some transplant centers as preferable alternatives to donors carrying mismatched antigens that are not crossreactive. The preference is based on the theory that HLA molecules that are more similar (belong to a crossreactive group or CREG) might be less immunogenic, a theory supported by a few small studies. 20 However, a current large study suggests that there is no difference in outcome between CREG-matched but antigen-mismatched donors and CREG-mismatched donors. 21 Second, these mismatched donors might be potentially mistyped and may actually carry the same antigen as the patient. For example, a donor typed as B71 might actually carry B72, since the serological distinction between these two antigens is difficult. 16, 22 A registry might wish to present these donors on the search report to aid the transplant center in the search. However, if listing these donors increases the size of the potential donor list for a specific patient so much that it might cause better matched donors to be missed, the registry might recommend alternative phenotype searches as an option for the transplant center. This option is only necessary when the initial list of potential donors is very limited.
It is therefore recommended that assignment of registry s.d. only include alternative splits in cases when the serological typing is almost always problematic (eg, B64 vs B65; B71 vs B72) and not consider antigens within CREG groups. The registry may elect also to sort crossreactive mismatches before others in lists of mismatched donors.
Alternate phenotype searches
Many registries routinely provide a listing of matched, potentially matched and limited mismatched (eg, one antigen-mismatched adult or two antigen-mismatched cord blood) donors in their search reports. The mismatched category, usually sorted to the bottom of the list, is used to select a partially mismatched donor if no matched donors are available, and to facilitate the search for mistyped donors. The registry should always allow a transplant center to submit alternative HLA assignments for a specific Selection of the alternative phenotypes should be assisted by a HLA expert, and should also be based on known misassignments and linkage disequilibria. 16, 22 Limitations in the HLA assignments accepted by the registry
Owing to the difficulty with assigning search determinants and linking serologic and DNA types for some HLA types, the registry may wish to restrict the resolution in the HLA typing that they will accept. For example, the registry may wish to require that all donor serologic types be provided at the split level of resolution or that all patient typings be provided at the allele level. 
Review of search determinants
Since information on the HLA system including the description of new alleles and the links between serologic and DNA types continues to grow, it will be important for each registry to review its search algorithms, including the assignment of search determinants on a routine basis. Individuals with HLA expertise should be included in these reviews and in the initial design of the search algorithm.
Selection of allele matches
As data continue to accumulate on the importance of allelelevel matches in transplant outcome, 24-28 many transplant centers are seeking an allele-matched donor at least at some HLA loci. In order to facilitate this, donors might be tested at levels of resolution which reduce the alternative allele possibilities. Testing at allele or intermediate level should be balanced, however, with the need for a large registry tested for HLA-A, -B, and -DRB1 types at a minimum. 29 
Prioritizing potentially matched donors
As described above, sorting of matches is usually performed after potential donors are selected based on s.d. matching. Some selected donors have a higher probability than other selected donors for being a match with the patient. This is usually the case for donors who have been tested by the more accurate DNA-testing method, especially if their assignments are at the allele level of resolution. The registry should prioritize these donors during the listing of potential matches by listing them first. For example, if a patient is typed as DRB1*1501, a potential donor typed as DRB1*1501 should be listed ahead of a donor typed as DR2. Thus, allele-matched donors should be prioritized ahead of potential matches, followed by mismatches. Within the potential matches, donors with a limited number of possible alternative alleles (eg, DRB1*1501 or *1503) should be prioritized ahead of donors with broader assignments (eg, DRB1*15 or DR2); however, the prioritization of potential matches by the number of alleles included may be misleading. For example, a donor characterized as DRB1*0401 or *0403 should not necessarily be prioritized ahead of a donor in which the allele combination includes more than these two assignments, since the number of alleles included in an assignment does not necessarily indicate the typing resolution. Even an allele level typing may be misleading regarding the resolution of the testing. 30 For example, a typing listing DRB1*0701 is not necessarily a higher resolution than a typing that lists only DRB1*07, since the first typing may have been obtained at a time in which only one DRB1*07 allele was known. One strategy might be to sort potential matches based on the population frequencies of alleles in the combination. Allele mismatches which share s.d. (eg, DRB1*1501 (SD02) donor and DRB1*1502 (SD02) patient) should appear below the potentially matched donors.
Sorting might also take into account additional loci like HLA-C which impact outcome. Volunteers, who are more extensively typed, for example those with HLA-C assignments potentially matching the patient, might be sorted above those with HLA-A, -B, and -DR only. HLA-C mismatches might sort below the donors without HLA-C typing.
The NMDP collects primary typing data so that older donor assignments can be reinterpreted when new alleles have been described. 5 This approach has its limitations in that reinterpreted assignments may no longer meet the registry's resolution requirements. In addition, information is lost when low-intermediate DNA-based typing information is summarized into a single assignment for submission to the registry. 5 For these reasons, the NMDP is evaluating the use of genotype lists, rather than summarized HLA types, for donor matching.
Understanding the strategy used in each registry
At the present time, some registries assign search determinants and matching relationships in their central office, whereas, others rely on their donor recruitment centers or HLA-typing laboratories to assign search determinants. In the latter case, each donor center or typing laboratory may use a slightly different strategy to assign search determinants, making it difficult for a registry to define its overall strategy and to provide documentation. It is strongly urged that each registry standardize the assignment of search determinants within its registry.
In any case, it is obvious that differing strategies among registries will result in the display of different sets of potential HLA matches for a given patient. It is critical for the transplant centers to understand the strategies in use in each registry in order to refine their own search strategies to best ascertain the donors they would want to select for more extensive HLA testing. World-wide standardization would facilitate this process; however, variations in the search algorithms used by different registries may make standardization difficult. In order to begin a discussion of these issues and standardization of approaches among registries worldwide, the NMDP has made its search determinants available to other registries on a website, www.nmdpresearch.org, under the HLA Resources section. Discussions among HLA and informatics experts from each registry and cord blood bank under the auspices of the World Marrow Donor Association and Netcord will enhance the consistency, power, and flexibility of the search algorithms used to identify donors for patients in need of a life-saving hematopoietic stem cell transplant.
